BioCryst Pharmaceuticals Inc. [NASDAQ: BCRX] traded at a high on 07/07/22, posting a 6.68 gain after which it closed the day’ session at $11.98. The company report on July 1, 2022 that BioCryst Presents New Data Demonstrating Consistently Low Attack Rates Among HAE Patients After Switching to ORLADEYO® (berotralstat).
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
—Analysis from APeX-S showed 98 percent attack-free days during treatment with ORLADEYO after switching from an injectable therapy—.
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new long-term efficacy and safety data from the APeX-2 and APeX-S clinical trials evaluating oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) showing sustained reductions in attack rates and improvement in quality of life (QoL) among patients living with HAE, and improved management of symptoms after switching to ORLADEYO from an injectable long-term prophylactic treatment (LTP).
The results of the trading session contributed to over 3876489 shares changing hands. Over the past one week, the price volatility of BioCryst Pharmaceuticals Inc. stands at 6.18% while the volatility over the past one month is 6.19%.
The market cap for BCRX stock reached $2.17 billion, with 184.90 million shares outstanding and 183.83 million shares in the current float. Compared to the average trading volume of 5.00M shares, BCRX reached a trading volume of 3876489 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about BioCryst Pharmaceuticals Inc. [BCRX]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BCRX shares is $17.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BCRX stock is a recommendation set at 2.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Barclays have made an estimate for BioCryst Pharmaceuticals Inc. shares, keeping their opinion on the stock as Equal Weight, with their previous recommendation back on April 18, 2022. While these analysts kept the previous recommendation, BofA Securities dropped their target price from $21 to $14. The new note on the price target was released on April 11, 2022, representing the official price target for BioCryst Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $16, while Oppenheimer analysts kept a Outperform rating on BCRX stock.
The Average True Range (ATR) for BioCryst Pharmaceuticals Inc. is set at 0.66, with the Price to Sales ratio for BCRX stock in the period of the last 12 months amounting to 11.54.
How has BCRX stock performed recently?
BioCryst Pharmaceuticals Inc. [BCRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 10.82. With this latest performance, BCRX shares gained by 15.08% in over the last four-week period, additionally sinking by -12.68% over the last 6 months – not to mention a drop of -24.61% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BCRX stock in for the last two-week period is set at 67.65, with the RSI for the last a single of trading hit 75.30, and the three-weeks RSI is set at 61.17 for BioCryst Pharmaceuticals Inc. [BCRX]. The present Moving Average for the last 50 days of trading for this stock 9.67, while it was recorded at 11.15 for the last single week of trading, and 13.23 for the last 200 days.
BioCryst Pharmaceuticals Inc. [BCRX]: Deeper insight into the fundamentals
BioCryst Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.10 and a Current Ratio set at 6.30.
Earnings analysis for BioCryst Pharmaceuticals Inc. [BCRX]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BCRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for BioCryst Pharmaceuticals Inc. go to 15.20%.
Insider trade positions for BioCryst Pharmaceuticals Inc. [BCRX]
There are presently around $1,529 million, or 71.60% of BCRX stock, in the hands of institutional investors. The top three institutional holders of BCRX stocks are: BLACKROCK INC. with ownership of 14,101,975, which is approximately -4.635% of the company’s market cap and around 0.90% of the total institutional ownership; VANGUARD GROUP INC, holding 13,207,040 shares of the stock with an approximate value of $158.22 million in BCRX stocks shares; and BAKER BROS. ADVISORS LP, currently with $152.28 million in BCRX stock with ownership of nearly 0% of the company’s market capitalization.
116 institutional holders increased their position in BioCryst Pharmaceuticals Inc. [NASDAQ:BCRX] by around 26,887,642 shares. Additionally, 96 investors decreased positions by around 16,559,211 shares, while 43 investors held positions by with 84,212,627 shares. The mentioned changes placed institutional holdings at 127,659,480 shares, according to the latest SEC report filing. BCRX stock had 50 new institutional investments in for a total of 10,632,129 shares, while 24 institutional investors sold positions of 2,176,589 shares during the same period.